Deupirfenidone for idiopathic pulmonary fibrosis
phase 3drug program · high · Wed Apr 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate deupirfenidone as an antifibrotic therapy for adults with idiopathic pulmonary fibrosis, aiming to slow lung function decline with favorable tolerability versus pirfenidone.
Randomized clinical trials comparing oral deupirfenidone with placebo and/or pirfenidone; pharmacokinetic, safety, tolerability, and efficacy assessment using forced vital capacity and adverse events.
A clinical trial published on 2026-04-01 is evaluating efficacy and safety of deupirfenidone compared with pirfenidone in adults with IPF over up to approximately 3 years.
In the 26-week ELEVATE-IPF phase 2b trial, deupirfenidone slowed FVC decline versus placebo; the 825 mg TID arm showed an adjusted mean FVC difference of 91.0 mL versus placebo with P = .02 and was generally safe and well tolerated.
Deupirfenidone and nintedanib drug-drug interaction study
phase 1drug program · high · Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Determine the potential for drug-drug interactions when deupirfenidone is co-administered with nintedanib.
Up to 60-day clinical pharmacokinetic, safety, and tolerability trial in healthy volunteers receiving deupirfenidone alone or with nintedanib.
Clinical trial record published on 2024-12-17.
Triglyceride-mimetic prodrugs for lymphatic drug delivery
preclinicalplatform · medium · Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Enhance lymphatic transport and lymph node exposure of immunomodulators through optimized lipid-mimetic prodrug design.
Preclinical prodrug optimization using mycophenolic acid conjugated to triglyceride-mimetic backbones with variable linker chain lengths and substitutions; lymphatic transport assessed in cannulated rats and lymph node exposure assessed in mice after oral administration.
2023 publication reported optimized linker designs that increased lymphatic transport and lymph node exposure.
Medium- to long-chain linkers, especially C12, improved lymphatic transport; C12 triglyceride-mimetic prodrugs produced greater than 40-fold increases in mesenteric lymph node exposure versus mycophenolic acid alone.
LYT-200 for relapsed or refractory AML and high-risk MDS
phase 1drug program · high · Mon Dec 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate LYT-200 in patients with relapsed or refractory acute myeloid leukemia or relapsed/refractory high-risk myelodysplastic syndrome.
Phase 1 open-label, multi-center clinical study assessing safety, pharmacokinetics, and anti-tumor activity.
Clinical trial record published on 2022-12-12.
LYT-300 in healthy volunteers and anxiety model
phase 1drug program · high · Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess orally administered LYT-300 for safety, tolerability, pharmacokinetics, food effect, multiple dosing, and pharmacodynamic or patient-reported response in a validated clinical model of anxiety.
Clinical study with single ascending dose, food-effect crossover, multiple ascending dose, and placebo-controlled pharmacodynamic assessment parts.
Clinical trial record published on 2021-12-07.
LYT-200 for locally advanced or metastatic solid tumors
phase 2drug program · high · Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate LYT-200 alone and in combination with chemotherapy or tislelizumab in patients with locally advanced or metastatic solid tumors.
Phase 1/2 open-label, multi-center clinical study assessing safety, pharmacokinetics, and anti-tumor activity.
Clinical trial record published on 2020-12-15.
LYT-100 for post-acute COVID-19 respiratory disease
phase 2drug program · high · Fri Dec 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate LYT-100 for safety and efficacy in adults with post-acute COVID-19 respiratory complications.
Randomized, double-blind, parallel-arm placebo-controlled study followed by an open-label extension for participants completing Part A.
Clinical trial record published on 2020-12-11.
